摘要
为评价银黄连翘散临床用药的安全性,根据《兽药研究技术指导原则》对其进行了急性毒性试验和长期毒性试验。急性毒性试验中小鼠随机分成5组,分别为空白对照组、低剂量组(3g/kg)、中剂量组(5g/kg)、高剂量组(10g/kg)、超高剂量组(20g/kg),经口灌服银黄连翘散,连续观察7d;长期毒性试验中大鼠随机分成4组,分别为空白对照组、低剂量组(6g/kg)、中剂量组(12g/kg)、高剂量组(24g/kg),每天灌胃一次,连续灌胃4周。结果显示:急性毒性试验中,两次重复试验LD50大于5 000mg/kg,属实际无毒;长期毒性试验中,大鼠体质量、饮水、采食量均无显著性差异,血常规、血生化检测,检测结果与对照组相比除单核细胞数、尿素含量有显著性差异外,其余均无显著性差异,脏器系数、病理切片高剂量组与对照组比较,没有明显病理变化。结果表明:在本试验条件下银黄连翘散安全无毒。
To evaluate clinical safety of Yinhuanglianqiao powder,test of acute toxicity and chronic toxicity were made according to toxicological evaluation procedures and methods.During the acute toxicity test,Kunming mice were randomly divided into 5groups,the four experimental groups were given Yinhuanglianqiao powder in dose of 3、5、10、20g/kg by intragastric adminstrition for 7days;During the chronic toxicity test,Wistar rats were randomly divided into 4groups,the three esperimental groups were given Yinhuanglianqiao powder in dose of 6、12、24g/kg by intragastric adminstrition for 30 days,once a day.The results showed that LD50 is greater than 5 000mg/kg during acute toxicity;In chronic toxicity test,weight、water intake、feed intake have no significant changes,monocytes、urea content appeared significant differences compared with that the in the control group,another indexes of hemotology appeared no differences compared with the control group.Histological examinations had no significant difference.In conclusion,the clinical medication of the Yinhuanglianqiao powder was safe under this experimental condition.
出处
《青岛农业大学学报（自然科学版）》
2015年第4期260-264,共5页
Journal of Qingdao Agricultural University(Natural Science)
基金
国家科技支撑计划:防治畜禽感染性疾病中兽药的创制及应用(2011BAD34)
关键词
银黄连翘散
急性毒性
长期毒性
Yinhuanglianqiao powder
acute toxicity
chronic toxicity
